Shreyasi Ghosh Ray

Jane-of-all-trades handling bizdev at Naari Pharma and clinical stage projects at Navad LifeSciences | 🎓: @UniofNottingham @bitspilaniindia | Views are my own.

[Shreyasi Ghosh Ray @SGR_v2]

Clinical trials are ultimately a waiting game with a frequent crossing of fingers.

[Shreyasi Ghosh Ray @SGR_v2]

I wish there was someone writing an article on the recent biotech / healthcare acquisitions taking place in Big Pharma — Merck + Cidara, Pfizer + Metsera, J&J + Halda, and now Abbott + Exact Sciences. Need to read a longform deep dive on these bets.

[Shreyasi Ghosh Ray @SGR_v2]

One of the coolest parts of my job (and the aspect that I am most grateful for) is that I get to marry the clinical / scientific standpoint with the business / market positioning. The flexibility that comes with it feels quite rare & special. I get to have my cake & eat it, too!

[Shreyasi Ghosh Ray @SGR_v2]

The roles are available in Noida. MBA grads with work ex in BD and/or pharma are preferred.

[Shreyasi Ghosh Ray @SGR_v2]

Hello, there are a few openings in my company in business development and associated roles. Do reach out if you are looking for openings allied to the above in the pharma / life sciences industry in India, happy to chat and explain more.

[Shreyasi Ghosh Ray @SGR_v2]

Hello, there are a few openings in my company in business development and associated roles. Do reach out if you are looking for openings allied to the above in the pharma / life sciences industry in India, happy to chat and explain more.

[Shreyasi Ghosh Ray @SGR_v2]

@AdrianoAguzzi Oh wow, that's quite a way to put it! Always interesting to hear the "lore" behind shifts like these. xD

[Shreyasi Ghosh Ray @SGR_v2]

Fantastic article, an absolute rollercoaster, and probably the best thing I've read this week. There is so much pharmaceutical "heritage" and Alex's narration makes it akin to reading about the metaphorical rise and decline of an empire.

https://t.co/kyDZt3LJyR

[Alex Kesin @alexkesin]

People often say biotech never had its own "Bell Labs," but it actually did: the Novartis Institutes for Biomedical Research.

My new piece about what made NIBR special, why it succeeded, and why pharma eventually turned away from its own breakthrough:

[Shreyasi Ghosh Ray @SGR_v2]

Opening and closing the eCRF tab like a fridge.

[Shreyasi Ghosh Ray @SGR_v2]

It's a vicious cycle with needs not being met for either party. In an ideal world, there'd be more observerships, internships, networking events, lab/factory tours, & case study comps for grads to understand what the industry involves & for professionals to bet on early talent

8

[Shreyasi Ghosh Ray @SGR_v2]

As a middle child of academia (Masters grad) who was looking for a "core pharma opening" ~2 years ago, it's strange to witness new grads apply for industry roles, (rightly) maximising their work ex, & then see the corp lens of *relevant* work ex being at odds with that effort.

1

[Shreyasi Ghosh Ray @SGR_v2]

Based on cursory LinkedIn scrolling, dept switches are common, with a median time of 5-8 years. A higher number of industry-academia collabs at undergrad+masters level may help to set expectations, but there'll be the logistics of resource allocation & data handling risks.

7

[Shreyasi Ghosh Ray @SGR_v2]

They should rename "Project Management" to "Professional Nagging".

[Shreyasi Ghosh Ray @SGR_v2]

@vfsglobalcare Sent.

[Shreyasi Ghosh Ray @SGR_v2]

Hi @IrlEmbIndia, your visa team in New Delhi has not responded despite repeated emails. Requesting you to expedite the visa decision as my travel for UK + Ireland is booked for late night on Jun-2/3 and I won't be able to travel unless my passport reaches Kolkata before that.